HCPCS J0603 is officially defined as "Sevelamer hydrochloride (renagel or therapeutically equivalent), oral, 20 mg (for esrd on dialysis)." HCPCS J0603 is referenced in 2 tracked payer policy changes from Aetna and Blue Cross and Blue Shield of Louisiana. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J0603 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Aetna is implementing multiple prior authorization changes for specialty drugs and procedures, removing precertification requirements for artificial insemination procedures, and requiring valid CPT/HCPCS codes for behavioral health services. Key changes take effect at various dates from November 2025 through February 2026.
Already effective July 1, 2025, Louisiana Blue accepts only the CAQH application for professional credentialing and recredentialing, and the Louisiana Standardized Credentialing Application was accepted for participating providers until June 30. Added codes in the Diagnostic and Therapeutic Services and Outpatient Procedure Services code ranges have effective dates of January 1, 2025 and April 1, 2025, including 15013, 15014, 38226 and 38227. For infusion therapy, the prior authorization must include all codes billed, including administration codes, or penalties will be applied to the claim.
Watch J0603
Get one email when a payer policy names J0603, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for J0603
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for J0603 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.